PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
JEAN-PAUL BRIAND *et al.*

Serial No.: 10/563,414

Filed: January 3, 2006

For: NOVEL IMMUNE BOOSTER COMPOUND, COMPOSITIONS COMPRISING THE SAME AND METHODS USING SAID BOOSTER COMPOUND

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: CHEP:016US

Confirmation No.: 5995

CERTIFICATE OF ELECTRONIC TRANSMISSION
37 C.F.R § 1.8

I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the date below:

February 12, 2007
Date

Mark B. Wilson

INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/CHEP:016US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Mark B. Wilson
Reg. No. 37,259
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: February 12, 2007

Form PTO-1449 (modified)	Atty. Docket No. CHEP:016US	Serial No. 10/563,414
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant JEAN-PAUL BRIAND *et al.*	
	Filing Date: January 3, 2006	Group: Unknown

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	2001/049357	12/06/01	Miller-Graziano *et al.*	514	12	12/04/00

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Translation Yes/No
	B1	EP1209226	05/29/02	Europe	English
	B2	WO 98/23728	06/04/98	WIPO	English
	B3	WO 01/92299	12/06/01	WIPO	English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Goxe *et al.*, "Simplified method to generate large quantities of dendritic cells suitable clinical applications," *Immunological Investigations*, 29:319-336, 2000
	C2	Kirby *et al.*, "Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein," *J Virol*, 74:2804-2813, 2000.
	C3	Magnusson *et al.*, "Genetic retargeting of adenovirus: novel strategy emplying "deknobbing" of the fiber," *J Virol*, 75:7280-7289, 2001.
	C4	Molinier-Frenkel *et al.*, "Adenovirus hexon protein is a potent adjuvant for activation of cellular immune response," *J Virol*, 76:127-135, 2002.
	C5	Molinier-Frenkel *et al.*, "Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T Lymphocytes," *J Virol.*, 74:7678-7682, 2000.
	C6	Molinier-Frenkel *et al.*, "The maturation of murine dendritic cells induced by human adenovirus is mediated by the fiber knob domain," *J Biol Chem.*, 278:37175-37182, 2003.
	C7	Morelli *et al.*, "Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway," *J Virol*, 74:9617-9628, 2000.

25639472.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. CHEP:016US	Serial No. 10/563,414
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant JEAN-PAUL BRIAND *et al.*	
(Use several sheets if necessary)	Filing Date: Jannary 3, 2006	Group: Unknown

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C8	Rea *et al.*, "Adenoviruses activate human dendritic cells without polarization toward a T-helper typre I-inducing subset," *J. Virol.*, 73:10245-10253, 1999.
	C9	Rea *et al.*, "Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells," *J. Immun.*, 166:5236-5244, 2001
	C10	Rouard *et al.*, "Adenoviral transduction of human "clinical grade" immature dendritic cells enhances costimulatory molecule expression and T-cell stimulatory capacity," *J. Immunol. Methods*, 241:69-81, 2000.

25639472.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.